tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
PremiumThe FlyFoghorn Therapeutics price target lowered to $12 from $14 at Jefferies
23d ago
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
Premium
Ratings
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
23d ago
Foghorn Therapeutics Announces $50 Million Equity Financing
Premium
Company Announcements
Foghorn Therapeutics Announces $50 Million Equity Financing
2M ago
Foghorn Therapeutics initiated with a Buy at Stifel
PremiumThe FlyFoghorn Therapeutics initiated with a Buy at Stifel
3M ago
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
Premium
Ratings
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
4M ago
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Premium
Company Announcements
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
4M ago
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
PremiumThe FlyFoghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
4M ago
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
Premium
Ratings
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
4M ago
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100